Business

Appalachian Mountain Brewery Announces Corporate Name Change and Entry into Hemp and CBD Markets

Appalachian Mountain Brewery Announces Corporate Name Change and Entry into Hemp and CBD Markets.

articleOptimus Healthcare Services, Inc.December 13, 20183/company/optimus-healthcare-services-inc/news/appalachian-mountain-brewery-announces-corporate-name-change-and-entry-into-hemp-and-cbd-markets
Appalachian Mountain Brewery Announces Corporate Name Change and Entry into Hemp and CBD Markets

About this update from Optimus Healthcare Services, Inc.

[{"type":"text","content":"NORTH MIAMI, FL / ACCESSWIRE / December 13, 2018 / Appalachian Mountain Brewery (OTC PINK: HOPS) (''AMB'') today announced a corporate name change to Between Dandelions, Inc. (hereafter ''BD'' or ''Company'') following the recent sale of all beer assets to Craft Brew Alliance. Following months of evaluation, research, development and guidance from the Strategic Advisory Board, management is excited to announce it has received final approval by the North Carolina Industrial Hemp Commission to cultivate and process Hemp and hemp-derived CBD products in North Carolina. The company will be heading in a new direction to pursue the Hemp and hemp-derived CBD markets effective immediately with the passage of the 2018 Farm Bill now fully legalizing Hemp and hemp-derived CBD so it is no longer a gray area marketplace. Sean Spiegelman, BD CEO, stated, ''Four years ago we began the navigation of leveraging a key strategic partnership in a booming market to expedite our corporate growth. We see the same opportunity today in the Hemp and hemp-derived CBD markets, and we expect to announce a similar strategic partnership with a leading vertically integrated Hemp and hemp-derived CBD operation soon. It is an exciting time for the Company as we leverage our prior success into a new direction which we believe provides greater potential for long-term shareholder value.'' The final 2018 Farm Bill has passed both the Senate and House and is expected to be signed by President Trump shortly. The final bill legalized hemp cultivation and will be a catalyst for explosive growth in a nascent industry that some forecast could top $20 billion by 2022. The lion's share of the roughly $800 million U.S. hemp market today is for products that include the non-psychoactive compound CBD, cannabidiol. Products infused with CBD are used for a wide range of medical conditions, ranging from epilepsy and multiple sclerosis to arthritis and chronic pain. Laws involving CBD products differ in each state. But of interest to public cannabis companies is the bill's implications for the U.S. market for cannabidiol, a "non-psychoactive" chemical found in hemp and marijuana. The legislation has been cited by numerous public cannabis companies as the catalyst to formally enter the American CBD market, according to Cowen analyst Vivien Azer. "This new [bill] vers...

More updates from Optimus Healthcare Services, Inc.